PONTE VEDRA, Fla.,
Dec. 19,
2023 /PRNewswire/ -- Cadrenal Therapeutics,
Inc., (Nasdaq: CVKD), a biopharmaceutical company developing
tecarfarin, a late-stage novel oral and reversible anticoagulant
(blood thinner) designed to prevent heart attacks, strokes and
deaths due to blood clots in patients with certain orphan diseases,
today announced that Noble Capital Markets ("Noble") has initiated
equity research coverage on the Company with an "Outperform" rating
and a price target of US$4.00 per
share. The full report by Noble Capital Markets Senior Life
Sciences Analyst Robert LeBoyer can
be obtained from
https://www.channelchek.com/research-reports/26351.
All reports on Cadrenal Therapeutics prepared by analysts
represent the views of such analysts and are not necessarily those
of the Company. Cadrenal Therapeutics is not responsible for the
content, accuracy, or timelines provided by analysts. Cadrenal
Therapeutics does not expressly or by implication warrant or assume
any legal liability or responsibility for the accuracy,
completeness, or usefulness of any information, assumption, data,
forecast, price target, estimate, or projection contained in the
reports or industry notes provided by analysts, and the
dissemination of such reports or industry notes does not
necessarily constitute or imply Cadrenal Therapeutics' endorsement
or recommendation. The Company is a participant in the Company
Sponsored Research Program ("CSRP") at Noble Capital Markets and
Noble Capital Markets receives compensation from the Company for
such participation. No part of the CSRP compensation was, is, or
will be directly or indirectly related to any specific
recommendations or views expressed by the analyst in this research
report.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal
Therapeutics is developing tecarfarin, a late-stage novel oral and
reversible anticoagulant (blood thinner), to prevent heart attacks,
strokes, and deaths due to blood clots in patients with certain
orphan diseases. Tecarfarin has orphan drug and fast track
designations for the prevention of systemic thromboembolism (blood
clots) of cardiac origin in patients with end stage kidney disease
(ESKD) and atrial fibrillation (AFib). Tecarfarin is specifically
designed to leverage a different metabolism pathway than the oldest
and most commonly prescribed Vitamin K Antagonist (warfarin).
Tecarfarin has been evaluated in eleven (11) human clinical trials
and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3
clinical trials, tecarfarin has generally been well-tolerated in
both healthy adult subjects and patients with chronic kidney
disease. For more information, please visit:
www.cadrenal.com.
About Noble Capital Markets
Noble Capital Markets,
Inc. was incorporated in 1984 as a full-service SEC / FINRA
registered broker-dealer, dedicated exclusively to serving
underfollowed small / microcap companies through investment
banking, wealth management, trading & execution, and equity
research activities. Over the past 37 years, Noble has raised
billions of dollars for these companies and published more than
45,000 equity research reports.
www.noblecapitalmarkets.com email:
contact@noblecapitalmarkets.com
About Channelchek
Channelchek (.com) is a
comprehensive investor-centric portal - featuring more than 6,000
emerging growth companies - that provides advanced market data,
independent research, balanced news, video webcasts, exclusive
c-suite interviews, and access to virtual road shows. The site is
available to the public at every level without cost or obligation.
Research on Channelchek is provided by Noble Capital Markets, Inc.,
an SEC / FINRA registered broker-dealer since 1984.
www.channelchek.com email: contact@channelchek.com
Cautionary Statement Regarding Forward-Looking
Statements
Any statements contained in this press release
about future expectations, plans, and prospects, as well as any
other statements regarding matters that are not historical facts,
may constitute "forward-looking statements." These statements
include statements regarding attaining the price target.
The words "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "will," "would" and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including the ability to reach the price
target of $4.00 per share, the
ability to advance tecarfarin within patients with implanted
medical devices for heart diseases as well as for the treatment of
patients with antiphospholipid syndrome who require chronic
anticoagulation, the ability to penetrate the U.S. market for
patients with LVADs and APS, the ability to advance patient care in
cardiovascular diseases and the other risk factors described in the
Company's Annual Report on Form 10-K for the year ended
December 31, 2022, and the Company's
subsequent filings with the SEC, including subsequent periodic
reports on Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K. Any forward-looking statements contained in this press
release speak only as of the date hereof and, except as required by
federal securities laws, the Company specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events, or otherwise.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/noble-capital-markets-initiates-coverage-on-cadrenal-therapeutics-with-outperform-rating-and-us4-00-price-target-302018426.html
SOURCE Cadrenal Therapeutics, Inc.